Skip to content

Newsroom


  • Page 1 of 4
  • 1
  • 2
  • 3
  • 4

Pharmacy Update April 2021

The changes in this bulletin apply to all groups that use the Lowest Net Cost Formulary. These changes include decisions that occurred as a result of our March 2021 Pharmacy and Therapeutics Committee (P&T) meeting. Members negatively impacted by one of these changes will be sent a letter in May.

Celebrating 40 Years in the Industry!

PAI’s journey, as a Third Party Administrator (TPA), began in 1981 with approximately 10 team members along with a desire to provide unprecedented service and value for self-funded administration of employee benefit plans to Palmetto State citizens. Over the years, PAI has evolved into a multi-faceted company with many offerings.

Pharmacy Bulletin-December 2020

The changes in this bulletin apply to all groups that use the Lowest Net Cost Formulary. These changes include decisions that occurred as a result of our November 2020 Pharmacy and Therapeutics Committee (P&T) meeting. Members negatively impacted by one of these changes will be sent a letter in January.

PAI October 2020 Pharmacy Bulletin

The changes in this bulletin apply to all groups that use the Lowest Net Cost Formulary. These changes include decisions that occurred as a result of our September 2020 Pharmacy and Therapeutics Committee (P&T) meeting. All changes are effective Jan. 1, 2021, unless otherwise noted. Members negatively impacted by one of these changes will be sent a letter in November.

Medication Adherence Program

The Medication Adherence program leverages analytics and timely interventions to improve adherence.

EMERGENCY PROCEDURES FOR PRESCRIPTION REFILLS

With the recent hurricanes affecting the Southeastern United States, we wish to update you on actions taken to aid our members in filing their prescriptions.

Pharmacy Update, July 2020

The changes in this bulletin apply to all groups that use the Net Cost Formulary. These changes include decisions that occurred as a result of our June 2020 Pharmacy and Therapeutics Committee (P&T) meeting.

Metformin ER Recall Alert

On May 28, 2020, the FDA announced that laboratory testing has revealed levels of N-nitrosodimethylamine (NDMA) above the agency’s acceptable intake limit in several lots of the extended-release (ER) formulation of metformin.

Formulary Update

The changes in this bulletin apply to all groups that use the Net Cost Formulary.

New Preferred Specialty Pharmacy Name

Effective immediately, the preferred specialty pharmacy for PAI will be known as Optum Specialty Pharmacy, formerly BriovaRx.

  • Page 1 of 4
  • 1
  • 2
  • 3
  • 4